メニューにジャンプ コンテンツにジャンプ

トップページ > 当センターについて > 業績集 > ACC業績集 2008年

ACC業績集 2008年

英文

ACC Publications 2008

※PubMed等(外部サイト)にリンクします

  1. Hayashida T, Gatanaga H, Tanuma J, and Oka S. Effect of low HIV-1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay. AIDS Res Hum Retrovirus 24: 495-498, 2008.
  2. Ueno T, Motozono C, Douki S, Mwimanzi, Rauch S, Fackler OT, Oka S, and Takiguchi M. Cytotoxic T lymphocyte-mediated selective pressure influences dynamic evolution and pathogenic functions of HIV-1 Nef. J Immunol 180: 1107-16, 2008
  3. Kawashima Y, Satoh M, Oka S, Shirasaka T, and Takiguchi M. Different immunodominance of HIV-1-specific CTL epitopes among 3 subtypes of HLA-A*26 associated with slow progression to AIDS. Biochem Biophys Res Commun 366: 612-616, 2008, Epub 2007 Nov 19.
  4. Gatanaga H, Honda H, and Oka S. Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics (review) 9: 207-214, 2008.
  5. Hachiya A, Kodama E, Sarafianos SG, Schuckmann MM, Matsuoka M, Takiguchi M, Gatanaga H, and Oka S. Amino acid mutation, N348I, in the connection subdomain of HIV-1 reverse transcriptase confers multi-class resistance to NRTIs and NNRTIs. J Virol 82: 3261-3270, 2008, Epub 2008 Jan 23.
  6. Tanuma J, Fujiwara M, Teruya K, Matsuoka S, Yamanaka H, Gatanaga H, Tachikawa N, Kikuchi Y, Takiguchi M, and Oka S. HLA-A*2402-restricted HIV-1-specific cytotoxic T lymphocytes and escape mutation after ART with structured treatment interruptions. Microbes Infect 10: 689-698, 2008, Epub 2008 Mar 29.
  7. Kitano M, Kobayashi N, Kawashima Y, Akahoshi T, Nokihara K, Oka S, and Takiguchi M. Identification and characterization of HLA-B*5401-restricted HIV-1-Nef and Pol-specific CTL epitopes. Microbes Infect 10: 764-772, 2008, Epub 2008 Apr 22.
  8. The Smart Study Group (Honda M and Ishisaka M as members of the trial and Oka S as a principal investigator of the Sydney Regional Coordinating Center). Major clinical outcomes in antiretroviral therapy (ART)-naïve participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 197: 1133-1144, 2008.
  9. The Smart Study Group (Honda M and Ishisaka M as members of the trial and Oka S as a principal investigator of the Sydney Regional Coordinating Center). Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4+ cell counts and HIV RNA levels during follow-up. J Infect Dis 197: 1145-1155, 2008.

和文

準備中

国際学会

準備中

国内学会

準備中